The EBIIA (Etude é pidé miologique Bacté rio-clinique des Infections Intra-Abdominales) study was designed to describe the clinical, microbiological and resistance profiles of communityacquired and nosocomial intra-abdominal infections (IAIs).
Introduction
National and international surveillance programmes have been developed to monitor the emergence of antibiotic resistance in bacteria. These studies are of major importance not only to report point prevalence of resistance, but also to detect trends over time. Some studies have highlighted the variation of resistance according to the isolated microorganisms and the antibiotic used. 1 -3 These surveys may provide guidance in choosing empirical antimicrobial therapy for selected infections.
In intra-abdominal infections (IAIs), several reports have emphasized the role of appropriate empirical antibiotic therapy to improve clinical success rates, reduce length of stay and decrease overall cost of hospitalization. 4 -7 The results of the microbiological analyses for a given patient thus have probably more importance for the therapeutic strategy, in particular in the adaptation of the initial antibiotic treatment. In this era of the broad spread of resistant microorganisms such as nosocomial and community extended-spectrum b-lactamase (ESBL) Enterobacteriaceae, community-acquired methicillin-resistant Staphylococcus aureus (MRSA), b lactam-and vancomycinresistant enterococci (VRE), the threat of resistance is a source of major concern for clinicians. In this setting, epidemiological surveys are of paramount importance to ensure adequacy of empirical antimicrobial treatment. Interestingly, few studies have highlighted the changes in resistance in IAI patients. This issue is of special interest with regard to patients with communityacquired infections in whom resistant pathogens are not commonly expected.
Therefore, the observational, national and prospective EBIIA study (Etude épidémiologique Bactério-clinique des Infections Intra-Abdominales) was designed to describe the clinical, microbiological and resistance profiles of community-acquired and nosocomial IAIs and to assess the therapeutic and prognosis features linked to resistant pathogens.
Patients and methods

Study population
Over a 6 month period (January to July 2005), this prospective multicentre observational study was performed in 25 medical institutions (11 in university teaching hospitals and 14 in non-teaching hospitals). Adult patients undergoing surgery or interventional drainage for IAI with positive microbiological culture (intra-abdominal samples from surgery or interventional drainage procedures) and identification of microorganisms were included in the database. The recruitment was exhaustive during the entire study. Patients with pancreatitis, primary peritonitis from cirrhosis or ascites were not included.
Study design
A Scientific Committee composed of seven clinicians was set up to validate the scientific quality of the project, the objectives and the methodology. The monitoring of the study was performed by the coordination centre of the study according to specific standardized procedures in order to check missing or incoherent data. The methods used for diagnosis were determined by the attending physicians and corresponded to the procedures applied in their institutions. The microbiological procedures corresponded to the procedures routinely used in the laboratory. Antimicrobial treatments were decided by the attending physicians.
According to French law, as this observational study did not modify the laboratory or clinical practices of the physicians, no informed consent and no approval of an Ethics Committee were required. However, all patients gave informed consent to participate and institutional review board approval was obtained. Approvals of the CNIL (National Data Protection Commission) and CCTIRS (Advisory Committee for data processing in terms of research in the field of health) were obtained, ensuring that patient data were kept confidential according to French regulations. The study met the quality standard described in the Declaration of Helsinki and the Good Epidemiological Practices.
Data collection
In each centre, the microbiologist identified as the centre coordinator and the attending physician collected the data in an electronic case report form. Case identification was triggered by the microbiologist after a positive peritoneal culture. After verification that the patient was eligible, microbiological and clinical data were recorded on the case report form. These data included: (i) identification of the sample; (ii) patient and disease characteristics, i.e. demography, type of infection (nosocomial versus community-acquired), severity criteria, co-morbidities and ASA (American Society of Anesthesiologists) score, previous curative antibiotic therapy within 7 days before surgery; (iii) surgical management, i.e. origin of infection, procedures applied and curative antibiotic therapy prescribed associated with the surgical intervention; and (iv) microbiological data, i.e. modalities of transport of samples, positive blood cultures, bacterial identification within peritoneal fluid, presence of yeasts and antibiotic susceptibilities of bacterial isolates according to the recommendations of the Antibiogram Committee of the French Microbiology Society. 8 
Definitions
IAIs were classified as community-acquired or nosocomial infections. Nosocomial IAI was defined as an infection absent upon admission that became evident 48 h or more after admission in patients hospitalized for a reason other than IAI. 9 Only patients with post-operative infections were considered as nosocomial cases. Co-morbidities included chronic renal failure, cardiac failure, diabetes mellitus, corticosteroids administered for more than 1 month and malignant diseases. The signs of severity were mechanical ventilation for .12 h, use of vasopressive (epinephrine, norepinephrine) agents, serum creatinine .150 mmol/L, prothrombin time ,30%, platelet count ,50000/mm 3 and ASA score .II. Microbiological analyses were performed according to the French REMIC recommendations 10 and susceptibility testing according to the recommendations of the Antibiogram Committee of the French Microbiology Society. 8 Empirical treatment was considered to be adequate when all the isolated bacteria were susceptible to at least one of the administered antibiotics and inadequate when antibiotic therapy disregarded at least one pathogen including Enterobacteriaceae, anaerobes, enterococci and yeasts.
Outcome
For outcome assessments, all patients were followed from the day of admission until hospital discharge. Study outcomes included re-operation for infection and death during hospitalization. Patients were deemed clinically cured if the patient was completely asymptomatic with respect to the original infection. All other situations corresponded to failure.
Statistical analysis
After double data entry into a computerized database, the statistical analysis was performed using the software package SAS 
Results
Patient and disease characteristics
Over the studied period, 331 patients (52% female, 61+20 years, range 18 -97 years) with microbiologically proven IAI were included, with a mean of 14.8 patients per centre (range 2 -36 patients). Among these patients, 234 community-acquired (71%) and 97 nosocomial (29%) infections were observed, yielding a total of 344 intraperitoneal specimens. Clinical status of patients at inclusion is described in Table 1 , and the surgical characteristics are presented in Table 2 . Co-morbidities and severity criteria at the time of diagnosis were more frequently observed in nosocomial infections when compared with community-acquired cases. Similarly, type and location of peritonitis differed in nosocomial and community-acquired cases.
Previous antibiotic therapy
Pre-operative antimicrobial treatment (within 7 days prior to surgery) had been given to 7% of the patients with communityacquired infections, mainly amoxicillin with clavulanic acid (n ¼ 16), whereas 55% of the cases in nosocomial infections received antibiotic agents in the interim before re-operation (P,0.001), mainly involving amoxicillin/clavulanic acid (n ¼ 10) or piperacillin/tazobactam (n ¼ 11) or a combination of various antimicrobials (n ¼ 32).
Microbiological results
The transport of the biological samples lasted more than 2 h in 30% and 31% of cases for community-acquired and nosocomial infections, respectively. Positive blood cultures were reported in 13 community-acquired (6%) and 8 nosocomial (8%) patients in the peri-operative period. The number of peritoneal (9) 23 (24) ,0.001 2 17 (7) 21 (22) ASA, American Society of Anesthesiologists physical status scale; NS, not statistically significant. microorganisms per sample was 3 in 34% and 54% of cases, respectively, for community-acquired and nosocomial infections (P, 0.001). A total of 829 microorganisms were cultured. The distribution of the microorganisms differed according to the nosocomial or community origin of the infection (Table 3) but not according to their location (data not shown). In nosocomial patients, increased proportions of aerobic bacteria were observed (P, 0.05) with increased proportions of Enterococcus faecalis (33% versus 19% in community-acquired patients; P,0.05) and Pseudomonas aeruginosa strains (13% versus 5% in community-acquired patients; P, 0.01). Conversely, decreased proportions of Escherichia coli (52% versus 72% in community-acquired patients, P,0.001) and streptococci strains were observed in nosocomial patients (31% versus 50% in community-acquired patients, P, 0.01). When taking into account prior antibiotic therapy, we did not observe any change in the type or proportion of the cultured organisms, whatever the type of infection.
In vitro antibiotic susceptibilities
Among the antimicrobial agents tested, the carbapenems (imipenem and ertapenem) and amikacin were the most consistently active in vitro against Enterobacteriaceae in both communityacquired and nosocomial infections (Table 4) . Against P. aeruginosa, amikacin, imipenem, ceftazidime and ciprofloxacin were the most active agents in community-acquired infections, while imipenem, cefepime and amikacin were the most active agents in nosocomial cases (Table 4) . No MRSA or VRE strains were cultured. When taking into account the global activity against the Gram-positive bacteria, vancomycin and teicoplanin were the most consistently active in vitro in both community-acquired and nosocomial infections, due to the strains of E. faecium (Table 5 ). Against the anaerobic bacteria, the most active agents were metronidazole and the two carbapenems, imipenem and ertapenem, in both community-acquired and nosocomial peritonitis (Table 6 ). When a comparison of previous antibiotic therapy and susceptibility testing was made, no specific mechanism of resistance was identified.
Antibiotic therapy
Antibiotic therapy adequately targeted the cultured pathogens after surgery for 63% of community-acquired and 64% of nosocomial peritonitis. The clinical status (co-morbidities or signs of severity) or the aetiology of peritonitis had no influence on the treatment adequacy except for the presence of biliary lesions in community-acquired infections. Empirical antibiotherapy was only appropriate in 15 cases (33%) with biliary lesions versus 81% in patients without biliary lesions (P,0.001).
Inappropriateness was linked to E. coli (n ¼ 11), Enterobacter spp. (n ¼ 5) and Klebsiella spp. (n¼ 5) strains not targeted by amoxicillin/clavulanic acid administered as monotherapy and E. faecalis (n¼ 4) and E. faecium (n ¼ 6) strains not targeted by cefotaxime or ceftriaxone.
Outcome
Subsequent re-operation for persistent infection was required for 7 community-acquired patients (3%) and 15 nosocomial patients (15%) (P, 0.001). Death during hospitalization was Table 4 . Proteus mirabilis 16 50 71 75 86 50 71 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 75 100 P. aeruginosa Table 6 . Antibiotic susceptibilities (% susceptible) of anaerobic bacteria isolated from patients with community-acquired (C) and nosocomial (N) IAIs
No. of isolates
100 100 100 100 100 83 100 83 100 100 100 100 100 100 100 100 77 67 100 100 100 100 A different bacteriological pattern of non-surviving compared with surviving patients was observed for community-acquired peritonitis with a significantly increased incidence of fatal cases of peritonitis with positive cultures of enterococci (20% versus 8%; P¼ 0.008), especially E. faecalis (23% versus 9%; P ¼ 0.03). In nosocomial peritonitis, no significant difference was evidenced between survivor and non-survivor patients linked to bacterial species cultured.
Using monovariate analyses, the presence of one or more co-morbidities, the presence of one or more severity criteria, a generalized peritonitis and the presence of enterococci had a statistically significant impact on death ( 
Discussion
This national, large-scale epidemiological and prospective study, performed over a short period of time, investigated the microbiological findings in a mixed group of patients with community-acquired and nosocomial IAIs. We assume that this descriptive study reflects 'real-life' conditions. The principal results are a higher diversity of microorganisms isolated in nosocomial infections and decreased susceptibility among these strains. Despite this, the adequacy of treatment is comparable in the two groups.
Several epidemiological studies addressing susceptibility testing in the course of IAIs published over recent years at an international level 1 -3 or a single centre level 11 -13 have made important contributions to the description of enteric microorganisms. In the studies by Paterson et al. 1 and Baquero et al.,
3
E. coli peritoneal isolates were 50% community-acquired and 50% hospital-acquired (isolated .48 h after hospitalization). The studies by Roehrborn et al., 11 Sotto et al. 12 and Seguin et al. 13 included various proportions of nosocomial and community-acquired infections (49%, 31% and 53% nosocomial infections and 51%, 69% and 47% community-acquired infections, respectively). However, from the perspective of clinicians in the field, these results are either too broad 1 -3 or too restrictive 11 -13 to be useful in clinical practice. Each type of study has its own deficiencies and strengths. Larger studies may show regional or even global trends that may not be apparent in smaller studies. 1 -3 Single centre studies have their own value by demonstrating local resistance patterns.
11 -13 Our study provides data situated between the two.
Our results confirm the difference in clinical and microbiological features between community-acquired and nosocomial peritonitis already observed in the rare comparative data available in the literature. 11, 12, 14 The main clinical differences between the community-acquired and nosocomial groups included a higher proportion of underlying disease and severity criteria at the time of diagnosis for nosocomial cases. The group of patients with nosocomial infections was, as expected, sicker with a large amount of co-morbidities. 5, 11, 13 The disease data referring to the source of infection, organs involved or type or source of peritonitis do not substantially differ from the data in the literature for either community-acquired or nosocomial infections.
-16
The bacterial spectrum observed in patients with community-acquired peritonitis matches the previous reports well, with E. coli, Streptococcus spp. and Bacteroides fragilis group as the most frequently isolated microorganisms.
11, 12, 16 High proportions of E. coli strains resistant to amoxicillin and amoxicillin/clavulanic acid are in line with previous reports. 12 ESBL-producing E. coli collected from IAIs may not be very prevalent in Europe or the USA, but have been reported with a relatively high prevalence in Latin America (16%) and Asia (25%). 3 However, this feature was not observed in the present study conducted during the same period (2005), for either community-acquired or nosocomial IAIs. Higher rates of emergence of ESBL-producing E. coli have been reported from other sites, reaching 1% in urinary tract isolates, 2.5% in respiratory tract infections or 1.5% in bloodstream infections in a nationwide study comprising more than 10 000 Enterobacteriaceae isolates. 17 This discrepancy between urinary tract and peritoneal samples has been previously described in Spain with 92% of ESBL-producing E. coli isolated from urine cultures and 1% from peritoneal fluid. 18 The low rate of ESBL strains and the low severity of the cases could explain the frequent prescription of amoxicillin/clavulanic acid in monotherapy in communityacquired peritonitis as reported previously. 16 Such an empirical policy should be revised and the antibiotic spectrum broadened. The French guidelines recommend the use of aminoglycosides when amoxicillin/clavulanic acid is prescribed to prevent therapy inadequacy, but these recommendations were obviously not closely followed in this study.
Overall, enterococci accounted for more than 10% of the isolates in community-acquired infections, a higher proportion than usually reported in the literature. In line with previous studies, the proportion of enterococci was increased in nosocomial cases when compared with community-acquired peritonitis.
11, 13, 14 However, the enterococcal proportions in nosocomial cases appear to be low when compared with other studies in nosocomial infections. 19 The low incidence of VRE in France, except for rare outbreaks, was confirmed by its absence during this survey. The need for a specific therapy against enterococci remains controversial. Neither French consensus nor IDSA (Infectious Diseases Society of America) guidelines recommend taking enterococci into account in community-acquired infections, whereas their treatment is required during nosocomial peritonitis. 20, 21 Several papers in the literature mention increased morbidity rates in patients with peritonitis and the presence of enterococci, 22 -24 but an increased mortality was only linked to enterococci in two papers. 12, 19 The increased mortality rate observed in our patients with community-acquired enterococcal infections was not confirmed in multivariate analysis. Until now, and on the basis of the data of this study, the ESBL-producing strains have not posed a clinical problem; however, if in the future clinicians must take ESBLs and enterococci into account, this will present difficulties in the choice of antibiotic.
The susceptibility of anaerobic organisms towards usual treatments remains good. However, the poor susceptibility of bacteroides against clindamycin should be stressed. This drug is no longer recommended for empirical treatment of communityacquired peritonitis because of its low efficacy. 20, 21 On the other hand, the efficacy of metronidazole and carbapenems remains remarkable both in community-acquired and nosocomial infections. These features raise the issue of routine identification and susceptibility testing of anaerobes in peritoneal samples. The IDSA guidelines consider that these procedures are unnecessary if broadly active anaerobic agents are used to treat infections in which anaerobes are frequently encountered and if adequate drainage or debridement is achieved. 21 However, susceptibility testing is the only way to report the prevalence of resistance and to detect trends over time. Thus, we assume that surveillance programmes involving susceptibility testing of anaerobic agents are mandatory.
Proportions of inadequate empirical antibiotic therapy were similar for both community-acquired and nosocomial patients. In previous reports of community-acquired IAIs, the incidence of inadequacy reached 13% 25 to 36% of the cases. 14 Our results for community-acquired peritonitis stand at a higher level of inadequacy, which could be explained by a high proportion of prescriptions of amoxicillin alone or combined with clavulanic acid towards E. coli, a somewhat insufficient regimen in many cases. In post-operative peritonitis, recent investigations have reported inadequacy in 35% to 40% of the cases, proportions that are close to those in our results.
11, 14 The current proportion of inadequacy was achieved despite a lower proportion of resistance than that observed in monocentric studies. 5 The IDSA guidelines advocate broad-spectrum single or combination therapy for high-risk patients with severe or post-operative nosocomial IAIs and to target enterococci. 21 The risk related to an inadequate empirical antibiotic therapy remains important in nosocomial peritonitis and is probably more life-threatening than excessive empirical treatment. 26 These features and recent guidelines plead for the use of expanded-spectrum multidrug regimens for empirical antibiotic therapy of nosocomial peritonitis followed by rapid de-escalation after microbiological identification of pathogens and susceptibility testing. 26, 27 The mortality rate reported in our study was in the range of those reported in the literature for community-acquired infections but appeared low for post-operative nosocomial infections. In the Roehrborn et al.
11 study, 9% of patients with community-acquired peritonitis died of complications versus 39% of patients with nosocomial peritonitis. In a recent study, focused on ICU patients, we reported 24% mortality in community-acquired peritonitis and 28% in nosocomial infection. 14 In the Sotto et al. 12 study, the mortality rate was 25% in a mixed population of patients with community-acquired and nosocomial peritonitis. A different bacteriological pattern between survivors and non-survivors was reported by Roehrborn et al.
11 with a lower incidence of E. coli and a higher incidence of Enterobacter species in non-survivor patients; this was not observed in the EBIIA study.
It has been shown that inadequate antimicrobial therapy prolongs hospitalization and is associated with clinical failure and a higher mortality rate. 4, 5, 20, 25 Inadequate therapy did not seem to be a factor for increased mortality in our study. However, this link between inadequacy and outcome was not found in several studies involving both community-acquired and nosocomial infections. 11, 12, 14 The low severity of our cases could explain these results. Indeed, the higher initial severity of the cases could enhance the role of inadequacy and poorer prognosis. 28 It could also be attributed to the definition of inadequacy used in this study, taking into account all the isolated strains, including enterococci in community-acquired infections, despite a low probability of pathogenicity in this clinical setting.
Surveillance studies have their own limitations. This is the case in the current investigation as a limited number of centres participated in the survey with heterogeneous activity and case-mix in teaching and non-teaching institutions. Results from these centres may not necessarily always be relevant to other French institutions. The lack of centralized microbiological analysis of the strains in a reference laboratory, which would have allowed complete susceptibility data availability, has to be mentioned. However, all microbiological laboratories follow the same guidelines issued by the French Microbiology Society, decreasing the heterogeneity. The significance of susceptibility test results obtained from studies involving fewer than 30 organisms is always difficult to interpret. 29 However, in the presence of limited data for antibiotic -bacteria couples, which is the case for IAIs, some results are published even with small numbers of strains. 1 -3 As this was an observational study, the treatment response was not monitored, which is a weakness in a study of a polymicrobial infection where the isolated microorganisms are not all responsible for the host response. In addition, adequacy of treatment is difficult to ascertain, since the adequacy of surgical treatment was not evaluated and is a major component of the success of IAI management. As a consequence, our results should be considered cautiously.
As there are only a few national reports on this topic, we assume that our results could be of value for the clinicians in the field. The information collected represents a first step towards analyses of longitudinal trends in antimicrobial resistance patterns among pathogens isolated from IAIs, which should be carried out in the future.
